A Pilot Study of Surgery and Chemotherapy Only as Initial Therapy for Children with Medulloblastoma

Full Title

Pilot Study of a Surgery and Chemotherapy-only Approach in the Upfront Therapy of Children with WNT Positive Standard Risk Medulloblastoma

Purpose

Medulloblastoma is a type of brain tumor in children. A particular subgroup of medulloblastoma, known as WNT-positive medulloblastoma, responds very well to treatment. Children with WNT-positive medulloblastoma are almost always cured with surgery followed by radiation therapy and chemotherapy, but the radiation can cause short-term and long-term side effects.

In this study, researchers want to see if giving only chemotherapy after surgery is effective enough to treat children with WNT-positive medulloblastoma, sparing patients from radiation and its side effects. Patients will receive nine cycles of chemotherapy after surgery.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have testing to determine if the brain tumor is WNT-positive medulloblastoma.
  • The tumor must have been almost completely removed after surgery.
  • Patients may not have received prior radiation therapy or chemotherapy for medulloblastoma.
  • This study is for children and adolescents ages 3 to 18 years.

For more information about this study and to inquire about eligibility, please contact Dr. Kevin De Braganca at 212-639-3449.

Protocol

17-473

Phase

Pilot

Disease Status

Newly Diagnosed

Investigator

Co-Investigators